32 results about "Enterotoxin gene" patented technology

The use of classical superantigens for treatment of cancer has resulted in a low response rates and serious toxicity in humans which is attributable, in part, to the presence of preformed superantigen specific antibodies in the plasma of treated patients. The present invention addresses this problem by providing a method for treating tumors comprising the administration of one or a plurality of egc (enterotoxin gene cluster) staphylococcal enterotoxins comprising staphylococcal enterotoxins G, I, M, N, O. These superantigens in native unmodified form can be administered intrathecally, intratumorally, intravenously to humans with advanced lung cancer while resolving pleural effusions and prolonging survival to 300% above control patients treated with talc pleurodesis. Intratumoral egc superantigens induces a significant and sustained reduction of the tumor size. In contrast to classic Sags, the egc superantigens induced minimal toxicity, are rarely associated with the presence of preformed antibodies and are used as a plurality with a broad T cell Vβ profile. Useful egc superantigen compositions for parenteral administration native egc enterotoxins, homologues, fragments and fusion proteins of native egc enterotoxins capable of activating a broad spectrum of T cells expressing T cell receptor/α motifs. T cell survival-enhancing cytokines IL-7, Il-15, Il-23 are used. together with parenteral egc SE therapy. Also disclosed is combined therapy that includes parenteral, intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs or (iii) radiation therapy or (iv) anti-angiogenic and tyrosine kinase inhibitors.

Provided are novel primers directed against enterotoxin A gene (ent A) of bacteria Staphylococcus aureus and primers directed against heat stable enterotoxin gene (yst) of bacteria Yersinia enterocolitica, for detecting poisoning in food articles. Also provided is a highly sensitive method for detecting bacterial food poisoning using the primers.

The invention provides a method for constructing a K88ac<+> enterotoxigenic escherichia coli attenuated virus strain. The method includes the following steps that 1, K88ac<+> enterotoxigenic escherichia coli enterotoxin genes are subjected to traceless point mutation, wherein TCT on the LT I gene of K88ac<+> enterotoxigenic escherichia coli without antibiotics resistance genes is mutated into AAA, and correspondingly-encoded No. 63 serine is mutated into lysine (K); 2, the K88ac<+> enterotoxigenic escherichia coli enterotoxin genes are knocked out, wherein on the basis of the first step, the ST II genes in the K88ac<+> enterotoxigenic escherichia coli are knocked out, and therefore the aim of attenuating the K88ac<+> enterotoxigenic escherichia coili is achieved accordingly. The attenuated virus strain constructed with the method is high in adhesivity and long in in-vivo planting time, infection of the pathopoiesia stain can be prevented, and the method can be used for biological preventing of colibacillosis caused by K88ac<+> ETEC.

The invention belongs to the field of biotechnological detection and particularly relates to a vibrio cholerae multiplex fluorescence PCR detection kit as well as preparation and application thereof. The kit provided by the invention comprises a vibrio cholerae hemolysin gene detection primer and a probe, a vibrio cholerae O1 antigen gene detection primer and a probe, vibrio cholerae O139 antigen gene detection primer and a probe and a vibrio cholerae enterotoxin gene detection primer and a probe. The kit has high detection sensitivity, the lowest detection limit is 1*10<3>copy/ml, and the accuracy and positive rate both reach 100%.

The invention relates to applications of Bacteroides fragilis in animal breeding, particularly to applications of Bacteroides fragilis in prevention and/or treatment of animal gastrointestinal diseases and in pharmaceutical compositions and feed additives, wherein the Bacteroides fragilis is ZY-312 and has the preservation number of CGMCC No.10685. According to the present invention, the Bacteroides fragilis ZY-312 does not contain the enterotoxin gene bft, has significant and high capabilities of cholate resistance and gastric acid resistance compared with the existing Bacteroides fragilis, can effectively prevent and/or treat animal gastrointestinal diseases, improves animal immunity and disease resistance, reduces animal prevalence, improves animal feed conversion rate, increases animal weight, promotes growth and development and production performance, can reduce the use of antibiotics, does not produce drug resistance, further has characteristics of safety and no toxicity, can improve the quality of products such as meat, eggs, milk and the like, can eliminate antibiotic drug residues, purify mew environment, and protects ecological environment.

The invention relates to applications of Bacteroides fragilis in prevention and/or treatment of meningitis, particularly to applications of Bacteroides fragilis in preparation of drugs, pharmaceutical compositions, foods, health products and food additives for prevention and/or treatment of meningitis, wherein the Bacteroides fragilis is ZY-312, is preserved in the China general microbiological culture collection center on April 2, 2015, and has the preservation number of CGMCC No.10685. According to the present invention, the Bacteroides fragilis provides good effects for prevention and/or treatment of meningitis, has characteristics of no drug resistance generation, safety, no toxicity, no enterotoxin gene bft and broad application prospects, and further has beneficial characteristics of cholate resistance, gastric acid resistance and the like compared with the existing strains.

The present invention relates to oligonucleotide primers having SEQ ID NOs. 1 to 21 specific for Salmonella enterotoxin gene (stn) gene, useful for rapid and specific screening of Salmonella. The present invention relates to a process for the rapid and specific detection of Salmonella enterotoxin gene (stn) gene in a subject for the presence of parasite Salmonella using oligonucleotide primers having SEQ ID NOs. 1 to 21 for Polymerase Chain Reaction (PCR), said process comprising the steps of preparing a DNA template, amplifying the template using the primers by PCR, running the PCR products on gel, and detecting the Salmonella.

The invention discloses CPA detection primers, a detection kit and a detection method for enterotoxin B-producing staphylococcus aureus. The CPA primers comprise stripping primers 4s and 5a, a cross amplification primer 2a1s, and specific primers 2a and 3a, wherein the nucleotide sequences of the above primers are respectively as shown in SEQ ID NO. 1 to SEQ ID NO. 5. A cross primer isothermal amplification reaction detection and identification system designed for the gene sequence of staphylococcus aureus enterotoxin B in by the invention overcomes the defects of long period, low sensitivity, high cost, difficulty in field application and the like of methods in the prior art. By selecting a conserved region of an enterotoxin B gene sequence of a target strain, a pair of the stripping primers, the cross primer and the specific primers are designed to construct a cross primer isothermal amplification reaction system, and a detection result is obtained within about 60 minutes, so the period of detecting enterotoxin B-producing staphylococcus aureus in the prior art is shortened.